AIDSmeds.com - Top Stories : Myriad Genetics Suspends Its HIV Maturation Inhibitor Program: "Myriad Genetics announced it is suspending its HIV drug development program and will focus instead on oncology drugs. The company says it is taking this step “for strategic, business reasons; and a reduction in workforce.”
Myriad had been developing a maturation inhibitor called bevirimat (MPC-4326, PA-457) since 2009, after purchasing the rights to the drug from Panacos Pharmaceuticals."
